Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Older Patients with Advanced-Stage Classical Hodgkin Lymphoma: Results of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA)

Herve Ghesquieres, MD PhD, Olivier Casasnovas, MD, Emmanuelle Nicolas-Virelizier, MD, Damaj Gandhi Laurent, MD PhD, Vincent Delwail, MD, Mohamed Touati, MD, Katell Le Du, MD, Franck Morschhauser, MD PhD, Christophe Bonnet, MD, Agathe Waultier-Rascalou, MD, Frederique Orsini-Piocelle, MD, Marc André, Myriam Ben Boutieb, Fabienne Morand, Diane Damotte, MD PhD, Alexandra Traverse-Glehen, MD PhD, Philippe Quittet, MD, Pauline Brice

Blood (2019) 134 (Supplement_1): 2832.

https://doi.org/10.1182/blood-2019-129016

Published: 2019

Journal Articles

Congenital FVIII/IX or VWF Deficiency Does Confer a Lower Rate of Myocardial Infarction-Related Mortality Despite Decreased Cardiovascular Interventions

Fateeha Furqan, MD, Nicolas Goldstein, Peter A. Kouides, MD

Blood (2019) 134 (Supplement_1): 1120.

https://doi.org/10.1182/blood-2019-131387

Published: 2019

Journal Articles

Use of Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL) in an Expanded Access Setting at Our Cancer Consortium

Blood (2018) 132 (Supplement 1): 2710.

https://doi.org/10.1182/blood-2018-99-116908

Published: 2018

Journal Articles

G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (GCLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Grade Myeloid Neoplasms: Final Results from a Phase 1/2 Trial

Anna B Halpern, MD, Emily M Huebner, Megan Othus, PhD, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Mary-Elizabeth M. Percival, MD, Paul C. Hendrie, MD PhD, Kelda M Gardner, PA-C, Sarah A Buckley, MD, Elihu H. Estey, MD, Roland B. Walter, MD PhD

Blood (2017) 130 (Supplement 1): 149.

https://doi.org/10.1182/blood.V130.Suppl_1.149.149

Published: 2017

Journal Articles

Phase 1 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Asma Anwar, MD, Anna B. Halpern, MD, Megan Othus, PhD, Bart L. Scott, MD, Paul C. Hendrie, MD PhD, Pamela S. Becker, MD PhD, Andrea M. Perdue, PA-C, Heather A. Smith, PA-C, Tara L. Chen, PharmD, Sarah A. Buckley, MD, Kaysey F. Orlowski, Morgan A. Powell, BS, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2015) 126 (23): 1339.

https://doi.org/10.1182/blood.V126.23.1339.1339

Published: 2015

Journal Articles

Orthotopic Heart Transplant Facilitated Autologous Hematopoietic Stem Cell Transplantation in Light-Chain Amyloidosis

Rammurti T Kamble, MD, Gloria Obi, PhD, Audrey Scholoff, MSN, George Carrum, MD, Lawrence Rice, MD, Arvind Bhimrajan, Jerry Estep

Blood (2015) 126 (23): 5364.

https://doi.org/10.1182/blood.V126.23.5364.5364

Published: 2015

Journal Articles

Prothrombin Complex Concentrates and Cardiac Surgery

Kamrouz Ghadmi, MD, Nazish Hashmi, MD, Jerrold Levy, MD, Thomas L. Ortel, MD, PhD, Ian J Welsby, MD

Blood (2015) 126 (23): 4712.

https://doi.org/10.1182/blood.V126.23.4712.4712

Published: 2015

Journal Articles

Cardiac Complications in Thrombotic Thrombocytopenic Purpura: Data from Nationwide Inpatient Sample

Ranjan Pathak, MD, Madan Raj Aryal, MD, Smith Giri, MD, Paras Karmacharya, MD, Anthony A Donato, MDMHPE

Blood (2014) 124 (21): 2793.

https://doi.org/10.1182/blood.V124.21.2793.2793

Published: 2014

Journal Articles

Ruxolitinib Prior to Allogeneic Stem Cell Transplantation Does Not Adversely Affect Post-Transplant Outcomes

Ahmad Hanif, MD, Parameswaran N. Hari, MD MRCP, MS, Ehab Atallah, MD, Karen-Sue B. Carlson, MD PhD, Marcelo C. Pasquini, MD, Laura C Michaelis, MD

Blood (2014) 124 (21): 1851.

https://doi.org/10.1182/blood.V124.21.1851.1851

Published: 2014

Journal Articles

A Phase I/II Trial Evaluating the Use of a Histone Deacetylase Inhibitor Panobinostat (LBH589) in Addition to Glucocorticoids in Patients with Acute Graft-Versus-Host Disease

Lia Perez, MD, Teresa Field, MD PhD, Marcie L Riches, MD MS, Hugo F Fernandez, MD, Frederick L Locke, MD, Brian C Betts, MD, Joseph Pidala, MD PhD, Erika Elmer, CCRP, Francisca Beato, BS, Maritza Lienlaf, MS, Pedro Horna, MD, Alejandro Villagra, PhD, Claudio Anasetti, MD

Blood (2014) 124 (21): 1167.

https://doi.org/10.1182/blood.V124.21.1167.1167

Published: 2014

Journal Articles

Comparison Between Saddle Versus Non-Saddle Pulmonary Embolism: Insights from Nationwide Inpatient Sample

Ranjan Pathak, MD, Smith Giri, MD, Madan Raj Aryal, MD, Paras Karmacharya, MD, Anthony A Donato, MDMHPE

Blood (2014) 124 (21): 3514.

https://doi.org/10.1182/blood.V124.21.3514.3514

Published: 2014

Journal Articles

Cardiac Toxicity Of High Dose Cyclophosphamide Post T Cell Replete HLA Haploidentical Hematopoietic Stem Cell Transplantation

Laetitia Souchet, MD, Julien Mayaux, MD, Damien Roosweil, MD, Madalina Uzunov, M.D., Alfred Le, Charles-Edouard Luyt, MD, Jean Paul Vernant, MD, Françoise Norol, MD, Hélène Treberden-Negre, MD, Nabih Azar, MD, Bénédicte Lebrun-Vigne, Delphine Callot, Ali Boudifa, Veronique Leblond, MD, Stéphanie Nguyen

Blood (2013) 122 (21): 5457.

https://doi.org/10.1182/blood.V122.21.5457.5457

Published: 2013

Journal Articles

Ruxolitinib Before Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Patients With myelofibrosis : a Preliminary Descriptive Report Of The JAK ALLO Study, a Phase II Trial Sponsored By Goelams-FIM In Collaboration With The Sfgmtc

Marie Robin, MD, PhD, Sylvie Francois, MD, Anne Huynh, Bruno Cassinat, PharmD, PhD, Jacques-Olivier Bay, MD, PhD, Jérôme Cornillon, MD, Valerie Rolland, Amandine Charbonnier, MD, Mauricette Michallet, MD, PhD, Françoise Boyer, Stephane Vigouroux, MD, Laure Vincent, MD, Ibrahim Yakoub-Agha, MD, PhD, Raphael Porcher, PhD, Gérard Socié, MD, PhD, Brigitte Dupriez, MD, Jean-Jacques Kiladjian, MD, PhD

Blood (2013) 122 (21): 306.

https://doi.org/10.1182/blood.V122.21.306.306

Published: 2013

Journal Articles

Orthotopic Heart Transplant Facilitated Autologous Hematopoietic Stem Cell Transplantation in Light-Chain Amyloidosis

Rammurti Kamble, MD, George Carrum, MD, Lawrence Rice, MD, John J. McCarthy, MD, Kelty R. Baker, MD, Carlos A. Ramos, MD, Horacio Adrogue, MD, Jerry Estep, MD

Blood (2011) 118 (21): 4489.

https://doi.org/10.1182/blood.V118.21.4489.4489

Published: 2011

Journal Articles

Heparin-Induced Thrombocytopenia: Comparison Between the Standard Gel-Particle Assay (PaGIA) and the Functional Flow Cytometric Assay.

Aaron Tomer, MD

Blood (2009) 114 (22): 5060.

https://doi.org/10.1182/blood.V114.22.5060.5060

Published: 2009

Journal Articles

Defibrotide: Seamless Phase I/II Dose Escalation Trial (ICSRI DF#1) to Stratify the Polypharmacology of a Cell Modulator to the Polypharmacology of Multi Organ Failure: Part I, Clinical Design, and Therapeutic Results

Arsinur Oral, MD

Blood (2008) 112 (11): 4316.

https://doi.org/10.1182/blood.V112.11.4316.4316

Published: 2008

Journal Articles

Japanese Guidelines for Pulmonary Thromboembolism (PTE) Prophylaxis Is Effective for a Decrease in the Incidence of PTE.

Takao Kobayashi, MD, PhD, Mashio Nakamura, MD, PhD, Masahito Sakuma, MD, PhD, Norikazu Yamada, MD, PhD, Norimasa Seo, MD PhD

Blood (2005) 106 (11): 4110.

https://doi.org/10.1182/blood.V106.11.4110.4110

Published: 2005

NARROW

Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Older Patients with Advanced-Stage Classical Hodgkin Lymphoma: Results of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA)

Congenital FVIII/IX or VWF Deficiency Does Confer a Lower Rate of Myocardial Infarction-Related Mortality Despite Decreased Cardiovascular Interventions

Use of Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL) in an Expanded Access Setting at Our Cancer Consortium

G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (GCLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Grade Myeloid Neoplasms: Final Results from a Phase 1/2 Trial

Phase 1 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Orthotopic Heart Transplant Facilitated Autologous Hematopoietic Stem Cell Transplantation in Light-Chain Amyloidosis

Prothrombin Complex Concentrates and Cardiac Surgery

Cardiac Complications in Thrombotic Thrombocytopenic Purpura: Data from Nationwide Inpatient Sample

Ruxolitinib Prior to Allogeneic Stem Cell Transplantation Does Not Adversely Affect Post-Transplant Outcomes

A Phase I/II Trial Evaluating the Use of a Histone Deacetylase Inhibitor Panobinostat (LBH589) in Addition to Glucocorticoids in Patients with Acute Graft-Versus-Host Disease

Comparison Between Saddle Versus Non-Saddle Pulmonary Embolism: Insights from Nationwide Inpatient Sample

Cardiac Toxicity Of High Dose Cyclophosphamide Post T Cell Replete HLA Haploidentical Hematopoietic Stem Cell Transplantation

Ruxolitinib Before Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Patients With myelofibrosis : a Preliminary Descriptive Report Of The JAK ALLO Study, a Phase II Trial Sponsored By Goelams-FIM In Collaboration With The Sfgmtc

Orthotopic Heart Transplant Facilitated Autologous Hematopoietic Stem Cell Transplantation in Light-Chain Amyloidosis

Heparin-Induced Thrombocytopenia: Comparison Between the Standard Gel-Particle Assay (PaGIA) and the Functional Flow Cytometric Assay.

Defibrotide: Seamless Phase I/II Dose Escalation Trial (ICSRI DF#1) to Stratify the Polypharmacology of a Cell Modulator to the Polypharmacology of Multi Organ Failure: Part I, Clinical Design, and Therapeutic Results

Japanese Guidelines for Pulmonary Thromboembolism (PTE) Prophylaxis Is Effective for a Decrease in the Incidence of PTE.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only